专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2022125928A1 METHODS AND COMPOSITIONS FOR IMPROVED PRODUCTION OF AN ANTIGEN FOR USE IN AN S. AUREUS VACCINE 审中-公开
公开(公告)号：WO2022125928A1
公开(公告)日：2022-06-16
申请号：PCT/US2021/062855
申请日：2021-12-10
申请人： BAYER ANIMAL HEALTH GMBH [DE]/[DE] , ILG, Thomas [DE]/[DE] , SCHAUER, Romina [US]/[US]
发明人： ILG, Thomas , SCHAUER, Romina
IPC分类号： C12N15/62 , A61K39/085 , A61P31/04 , C07K14/31
摘要： The present invention relates to an improved antigen derived from Staphylococcus aureus and uses thereof against Staphylococcus infections, such as bovine intramammary infections. In particular, a modified SACOL1867 polypeptide is provided comprising a mutation at one or more amino acid positions, wherein at least one of the mutations disrupts the catalytic binding site and/or decreases proteolytic activity of the modified SACOL1867 polypeptide compared to a reference SACOL1867 polypeptide. Fusion polypeptides comprising a modified SACOL1867 polypeptide of the invention are also provided, as well as vaccine compositions comprising the modified SACOL1867 polypeptides and/or fusion polypeptides thereof.

2. 发明申请

WO2022040768A1 COMPOSITIONS FOR USES IN METHODS OF TREATING CORONAVIRUS INFECTIONS 审中-公开
公开(公告)号：WO2022040768A1
公开(公告)日：2022-03-03
申请号：PCT/BR2021/050367
申请日：2021-08-27
申请人： NOWILL, Alexandre Eduardo
发明人： NOWILL, Alexandre Eduardo
IPC分类号： A61K39/00 , A61K39/002 , A61K39/02 , A61K39/04 , A61K39/085 , A61K39/09 , A61K39/108 , A61K39/112 , A61K39/12 , A61K38/43 , A61K38/46 , A61P31/14 , A61P37/02
摘要： Disclosed herein are immunomodulatory compositions useful for the treatment of SARS-CoV-2 infection and symptoms related to COVID-19, such as the cytokine storm. The immunomodulatory compositions comprise two or more antigenic agents presenting pathogen-associated molecular patterns (PAMPS) and/or danger associated molecular patterns (DAMPS) and physiologically acceptable carriers, excipients, diluents or solvents.

3. 发明申请

WO2021127653A1 COMPOSITIONS AND METHODS FOR IMMUNIZATION AGAINST STAPHYLOCOCCUS AUREUS 审中-公开
公开(公告)号：WO2021127653A1
公开(公告)日：2021-06-24
申请号：PCT/US2020/066463
申请日：2020-12-21
申请人： WASHINGTON UNIVERSITY
发明人： WARDENBURG, Juliane Bubeck , LEE, Brandon , OLANIYI, Reuben
IPC分类号： A61K39/085 , A61P31/04 , A61P37/04 , C07K14/31 , A61K39/00
摘要： Among the various aspects of the present disclosure relates to methods and compositions useful to reduce or prevent tolerogenic or suppressive T-cell responses in a subject to a bacterial pathogen. The methods include exposing the subject to an modified bacterial antigen prior to the first exposure of the subject to the bacterial pathogen. The vaccination strategy is capable of neutralizing Hla to provide immunoprotection against S. aureus infections.

4. 发明申请

WO2019217243A1 METHODS AND COMPOSITIONS RELATED TO THE NEXT GENERATION VACCINE 审中-公开
公开(公告)号：WO2019217243A1
公开(公告)日：2019-11-14
申请号：PCT/US2019/030694
申请日：2019-05-03
申请人： UNIVERSITY OF KANSAS
发明人： PICKING, Wendy L. , PICKING, William D.
IPC分类号： A61K38/00 , A61K38/16 , A61K39/00 , A61K39/02 , A61K39/085
摘要： Disclosed are methods and compositions related to polypeptides comprising a fusion of the needle tip protein and translocator protein of a type III secretion apparatus (T3SA) from a type III secretion system (T3SS) of a Gram negative bacteria. Disclosed herein are fusion polypeptides comprising a fusion of a needle tip protein, such as, Bsp22, LcrV, BipD, PcrV, CT053, or CT668, or an antigenic fragment thereof; and a translocator protein, such as, BopB, YopB, BipB, PopB, CopB, or CopB2, or an antigenic fragment thereof from a Type III secretion system (T3SS) of a Gram negative bacteria, such as, Bordetella, Burkholderia, Chlamvdia, Pseudononas, Vibrio, or Yersinia.

5. 发明申请

WO2019121926A1 IMMUNOGENIC COMPOSITION 审中-公开
公开(公告)号：WO2019121926A1
公开(公告)日：2019-06-27
申请号：PCT/EP2018/085857
申请日：2018-12-19
申请人： GLAXOSMITHKLINE BIOLOGICALS SA
发明人： FARIDMOAYER, Amirreza , GERBER, Sabina Marietta , KEMMLER, Stefan Jochen
IPC分类号： C07K14/31 , A61P31/04 , A61K39/085
CPC分类号： A61P31/04 , A61K39/085 , A61K2039/6068 , C07K14/31
摘要： The present invention discloses modified Staphylococcus aureus ClfA proteins that contain glycosylation site consensus sequences. The invention also discloses a conjugate comprising a modified ClfA protein and an antigen (for example a Staphylococcus aureus saccharide antigen), wherein the antigen is linked (either directly or through a linker)to an amino acid residue of the modified ClfA protein.

6. 发明申请

WO2019121924A1 IMMUNOGENIC COMPOSITION 审中-公开
公开(公告)号：WO2019121924A1
公开(公告)日：2019-06-27
申请号：PCT/EP2018/085854
申请日：2018-12-19
申请人： GLAXOSMITHKLINE BIOLOGICALS SA
发明人： BRAUN, Martin , FARIDMOAYER, Amirreza , GERBER, Sabina Marietta , MÜLLER, Markus
IPC分类号： A61K39/085 , C07K14/31 , A61P31/04
摘要： The present invention discloses modified Staphylococcus aureus HIa proteins which show reduced tendency to aggregate, improving protein stability and yield. Said modified HIa proteins optionally also contain glycosylation site consensus sequences. The invention also discloses a conjugate comprising a modified HIa protein and an antigen (for example a Staphylococcus aureus saccharide antigen), wherein the antigen is linked to an amino acid residue of the modified HIa protein.

7. 发明申请

WO2019116392A1 THERAPEUTIC BACTERIOCINS 审中-公开
公开(公告)号：WO2019116392A1
公开(公告)日：2019-06-20
申请号：PCT/IN2018/050837
申请日：2018-12-13
申请人： GANGAGEN, INC. , AMBADY, Anisha
发明人： AMBADY, Anisha , APPAIAH, Chemira Biddappa , BALASUBRAMANIAN, Deepak , PAUL, Vivek Daniel , SARAVANAN, R. Sanjeev , SHARMA, Umender Kumar
IPC分类号： A01N63/02 , A61K38/16 , A61K38/43 , A61K38/50 , A61K39/085 , A61K39/108 , C07K14/195 , C07K14/21 , C07K14/245
摘要： The present invention provides methods and compositions to reduce growth of microbial colonies, including infections, and includes therapeutic compositions, methods for treatment of infections, and methods for identifying additional such compositions.

8. 发明申请

WO2019050815A1 PNEUMOCOCCAL POLYSACCHARIDES AND THEIR USE IN IMMUNOGENIC POLYSACCHARIDE-CARRIER PROTEIN CONJUGATES 审中-公开
公开(公告)号：WO2019050815A1
公开(公告)日：2019-03-14
申请号：PCT/US2018/049308
申请日：2018-09-04
申请人： MERCK SHARP & DOHME CORP. , PORAMBO, Richard, J. , ABEYGUNAWARDANA, Chitrananda , MUSEY, Luwy Kavuka , KOSINSKI, Michael, J. , CUI, Yadong Adam , MCHUGH, Patrick , KONIETZKO, Janelle
发明人： PORAMBO, Richard, J. , ABEYGUNAWARDANA, Chitrananda , MUSEY, Luwy Kavuka , KOSINSKI, Michael, J. , CUI, Yadong Adam , MCHUGH, Patrick , KONIETZKO, Janelle
IPC分类号： A61K31/35 , A61K31/715 , A61K39/085 , C12P19/04
摘要： The present invention provides capsular polysaccharides from Streptococcus pneumoniae serotypes identified using NMR. The present invention further provides polysaccharide-protein conjugates in which capsular polysaccharides from one or more of these serotypes are conjugated to a carrier protein such as CRM197. Polysaccharide-protein conjugates from one or more of these serotypes may be included in multivalent pneumococcal conjugate vaccines having polysaccharides from multiple additional Steptococcus pneumoniae serotypes.

9. 发明申请

WO2019050813A1 PNEUMOCOCCAL POLYSACCHARIDES AND THEIR USE IN IMMUNOGENIC POLYSACCHARIDE-CARRIER PROTEIN CONJUGATES 审中-公开
公开(公告)号：WO2019050813A1
公开(公告)日：2019-03-14
申请号：PCT/US2018/049305
申请日：2018-09-04
申请人： MERCK SHARP & DOHME CORP. , PORAMBO, Richard, J. , ABEYGUNAWARDANA, Chitrananda , MUSEY, Luwy, Kavuka , KOSINSKI, Michael, J. , CUI, Yadong, Adam
发明人： PORAMBO, Richard, J. , ABEYGUNAWARDANA, Chitrananda , MUSEY, Luwy, Kavuka , KOSINSKI, Michael, J. , CUI, Yadong, Adam
IPC分类号： A61K31/35 , A61K31/715 , A61K39/085 , C12P19/04
摘要： The present invention provides capsular polysaccharides from Streptococcus pneumoniae serotypes identified using NMR. The present invention further provides polysaccharide-protein conjugates in which capsular polysaccharides from one or more of these serotypes are conjugated to a carrier protein such as CRM197. Polysaccharide-protein conjugates from one or more of these serotypes may be included in multivalent pneumococcal conjugate vaccines having polysaccharides from multiple additional Steptococcus pneumoniae serotypes.

10. 发明申请

WO2018072031A1 VACCINE CONSTRUCTS AND USES THEREOF AGAINST STAPHYLOCOCCUS INFECTIONS 审中-公开
标题翻译：疫苗构建及其对抗金色葡萄球菌感染的用途
公开(公告)号：WO2018072031A1
公开(公告)日：2018-04-26
申请号：PCT/CA2017/051253
申请日：2017-10-20
申请人： SOCPRA SCIENCES ET GÉNIES S.E.C.
发明人： MALOUIN, François , STER, Céline , CÔTÉ-GRAVEL, Julie , BROUILLETTE, Éric
IPC分类号： C07K14/31 , A61K39/085 , A61P31/04 , A61P37/04 , C07K19/00 , C12N1/21 , C12N15/31 , C12N15/62 , C12N15/63
摘要： There is provided a fusion construct of formula (I): X-A-linker-B-Z (I) wherein : (1) A and B are identical or different and are independently: (a) a polypeptide comprising a SACOL0029 polypeptide as set forth in any one of the sequences depicted in FIG. 24 (SEQ ID NOs: 5 and 121 to 131), a SACOL0264 polypeptide (SEQ ID NO : 185), a SACOL0442 polypeptide as set forth in any one of the sequences depicted in FIG. 22D (SEQ ID NOs: 29 and 82 to 92), a SACOL0718 polypeptide (SEQ ID NO : 186), a SACOL0720 polypeptide as set forth in any one of the sequences depicted in FIGs. 23I-J (SEQ ID NOs: 11 and 109 to 120), a SACOL1353 polypeptide (SEQ ID NO : 187), a SACOL1416 polypeptide (SEQ ID NO : 188), a SACOL1611 polypeptide (SEQ ID NO : 189), a SACOL1867 polypeptide as set forth in any one of the sequences depicted in FIG. 25D (SEQ ID NOs: 152 to 164), a SACOL1912 polypeptide (SEQ ID NO : 43), a SACOL1944 polypeptide (SEQ ID NO : 190), a SACOL2144 polypeptide (SEQ ID NO : 191), a SACOL2365 polypeptide (SEQ ID NO : 192), a SACOL2385 polypeptide (SEQ ID NO : 50) or a SACOL2599 polypeptide (SEQ ID NO : 193), based on the gene nomenclature from the Staphylococcus aureus COL (SACOL) genome set forth in NCBI Reference Sequence NC_002951.2; (b) a polypeptide encoded by a gene from a same operon as a gene encoding the polypeptide of (a); (c) a polypeptide comprising an immunogenic fragment of at least 13 consecutive amino acids of (a) or (b); (d) a polypeptide comprising an amino acid sequence at least 60% identical overall to the sequence of the polypeptide of any one of (a) to (c); or (e) a polypeptide comprising an immunogenic variant comprising at least 13 consecutive amino acids of any one of (a) to (c); (2) the linker is an amino acid sequence of at least one amino acid or is absent; (3) X is absent or is an amino acid sequence of at least one amino acid; and (4) Z is absent or is an amino acid sequence of at least one amino acid. Also provided are compositions and kits comprising the fusion and uses of these fusions, compositions and kits.
摘要翻译：提供了式（I）的融合构建体：XA-接头-BZ（I）其中：（1）A和B相同或不同，并且独立地：（a）包含如图1所示的任何一个序列中所列的SACOL0029多肽。 24（SEQ ID NO：5和121至131），SACOL0264多肽（SEQ ID NO：185），SACOL0442多肽，如图1所示任何一种序列中所述。 22D（SEQ ID NO：29和82至92），SACOL0718多肽（SEQ ID NO：186），SACOL0720多肽，如图1和2所示的任何一种序列中所示。 23I-J（SEQ ID NO：11和109-120），SACOL1353多肽（SEQ ID NO：187），SACOL1416多肽（SEQ ID NO：188），SACOL1611多肽（SEQ ID NO：189），SACOL1867 如图1所示的任何一个序列中所述的多肽。 25D（SEQ ID NO：152至164），SACOL1912多肽（SEQ ID NO：43），SACOL1944多肽（SEQ ID NO：190），SACOL2144多肽（SEQ ID NO：191），SACOL2365多肽基于来自NCBI参考序列NC_002951.2中阐述的金黄色葡萄球菌COL（SACOL）基因组的基因命名，SACOL2385多肽（SEQ ID NO：50）或SACOL2599多肽（SEQ ID NO：193） ; （b）由与编码（a）的多肽的基因来自相同操纵子的基因编码的多肽; （c）包含（a）或（b）的至少13个连续氨基酸的免疫原性片段的多肽; （d）包含与（a）至（c）中任一项的多肽序列总体上至少60％相同的氨基酸序列的多肽; 或（e）包含免疫原性变体的多肽，所述免疫原性变体包含（a）至（c）中任一项的至少13个连续氨基酸; （2）接头是至少一个氨基酸的氨基酸序列或不存在; （3）X不存在或是至少一个氨基酸的氨基酸序列; 和（4）Z不存在或是至少一个氨基酸的氨基酸序列。还提供了包含这些融合物，组合物和试剂盒的融合和用途的组合物和试剂盒。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式